CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Avantogen Oncology, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Avantogen Oncology, Inc.
2121 Avenue of the Stars
#2460
Phone: (310) 553-5533p:310 553-5533 Los Angeles, CA  90067-5010  United States

This company is no longer actively traded on any major stock exchange.

Business Summary
Avantogen Oncology, Inc., formerly known as Innovate Oncology, Inc., acquires, develops and seeks to commercialize compounds to treat various types of cancer. Prior to the May 26, 2006, Acquisition, the Company had been pursuing financing for a portfolio of products. The Company focused its resources on three particular product candidates: Chemo-resistance Inhibitor (RP101), Capridine beta and oral paclitaxel. In November 2006, after further evaluation of its existing pipeline, the Company decided to terminate its license agreement for oral paclitaxel. In connection with the May 26, 2006, Acquisition, the Company changed its name to Avantogen Oncology, Inc. from Innovate Oncology, Inc. (Innovate). In November 6, 2006, the Company, Gardant Pharnaceuticals, Inc. (Gardant) and Supratek Pharma, Inc. (SPI) entered into a termination of agreement and releases.
(Source: 10KSB)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/200712/31/2006YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer WilliamArdrey 41
Chief Financial Officer, Director MichaelHillmeyer 50 7/11/2007 1/24/2007
Director Lee J.Cole 50 5/26/2006 5/26/2006

Business Names
Business Name
Avantogen Oncology Inc.
AVTO
Cynat Oncology, Inc.
FCRS
Innovate Oncology, Inc.
Resistys, Inc.

General Information
Number of Employees: 2 (As of 12/31/2005)
Outstanding Shares: 74,282,472 (As of 10/24/2007)
Shareholders: 769
Stock Exchange: OTC
Federal Tax Id: 870438641


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023